Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30753587 | 1.00 | DPP4 (0.41) | DPP4GAAMAPTKDM4ETSHR | |
| SCHEMBL22557290 | 0.87 | DPP4 (0.47) | DPP4GAAMAPTKDM4ETSHR | |
| SCHEMBL29158125 | 0.77 | AGBL2 (0.44) | DPP4GAAKDM4ETSHRALDH1A1 | |
| SCHEMBL22557745 | 0.76 | DPP4 (0.44) | DPP4GAAKDM4EHTTALDH1A1 | |
| SCHEMBL15544893 | 0.74 | ADORA2A (0.42) | DPP4TSHRMAPK1ALDH1A1 | |
| SCHEMBL17512545 | 0.73 | TKT (0.30) | — | |
| SCHEMBL17512483 | 0.73 | THRB (0.35) | MAPTTSHRALDH1A1 | |
| SCHEMBL2616551 | 0.71 | FYN (0.44) | GAAMAPTKDM4ETSHRMAPK1 | |
| SCHEMBL15543726 | 0.70 | MAPT (0.40) | GAAMAPTKDM4ETSHRMAPK1 | |
| SCHEMBL115432 | 0.70 | PIK3CA (0.42) | GAAMAPTKDM4ETSHRMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113710664-B | JAK1 selective kinase inhibitors | 迪哲(江苏)医药股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3956322-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-23 | — | — | EP | disclosed |
| CN-113710664-A | JAK1 selective kinase inhibitors | 迪哲(江苏)医药股份有限公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2020211839-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020211839-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | JAK1, JAK2, JAK3 | DPP4 3476/4885GAA 2309/4885MAPT 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.